Filing Flows

Filing Flows › Companies › AIM ImmunoTech › Cash flow

AIM ImmunoTech cash flow, quarter by quarter

Latest: Q2 2026 · from the cash-flow statements filed with the SEC

Free cash flow−$4.6M in Q2 2026 · −$14.4M over twelve months

Operating cash flow−$4.6M
Free cash flow−$4.6M

Analysis

In Q2 2026, AIM ImmunoTech generated −$4.6M of operating cash flow. That is $3.1M less than in Q2 2025 (−$1.5M).

Over the twelve months to Jun 30, 2026, operating cash flow was −$14.4M; the largest uses were operating cash flow ($14.4M); besides operations, cash came from other financing ($23.7M), other investing ($52K); the cash balance rose by $9.4M.

Operating cash flow was −$4.6M against net income of −$3.8M. The largest differences: depreciation & amortization +$44K, prepaid and other assets −$27K, gains on investments +$1K.

Free cash flow

AIM ImmunoTech: free cash flow by quarterAIM ImmunoTech: free cash flow by quarter−$3.1MQ3 2024−$4.0MQ4 2024−$2.4MQ1 2025−$1.5MQ2 2025−$5.1MQ3 2025−$2.0MQ4 2025−$2.7MQ1 2026−$4.6MQ2 2026
Operating cash flow less capital spending.
AIM ImmunoTech: operating cash flow against capital spendingAIM ImmunoTech: operating cash flow against capital spendingOperating cash flowCapital spending−$3.1M$0Q3 2024−$4.0M$0Q4 2024−$2.4M$0Q1 2025−$1.5M$0Q2 2025−$5.1M$0Q3 2025−$2.0M$0Q4 2025−$2.7M$0Q1 2026−$4.6M$0Q2 2026
Latest (Q2 2026): Operating cash flow −$4.6M, Capital spending $0.

Capital allocation, year by year

AIM ImmunoTech: where the cash came from (up) and went (down), by fiscal yearAIM ImmunoTech: where the cash came from (up) and went (down), by fiscal yearOperating cash flowNet borrowingShares issuedAsset salesCapital spendingFY2021: Operating cash flow −$14.0MFY2021: Net borrowing −$4.7MFY2021: Shares issued $13.0MFY2021: Asset sales $245KFY2021: Capital spending −$41K$13.3MFY2021FY2022: Operating cash flow −$16.1MFY2022: Shares issued $80KFY2022: Asset sales $3.9MFY2022: Capital spending −$86K$4.0MFY2022FY2023: Operating cash flow −$21.3MFY2023: Shares issued $485KFY2023: Asset sales $47K$532KFY2023FY2024: Operating cash flow −$14.9MFY2024: Net borrowing $2.2MFY2024: Shares issued $892KFY2024: Capital spending −$18K$3.1MFY2024FY2025: Operating cash flow −$11.0MFY2025: Net borrowing $2.1M$2.1MFY2025
Over these 5 years operating cash flow totalled −$77.2M; the largest uses were operating cash flow ($77.2M) and net borrowing ($4.7M). Cash-flow statements as filed.

Cash runway and the debt wall

Cash & investments$10.0M
Debt$3.6M
Net cash$6.3M
Due within a year$3.6M
Cash runway8 months

AIM ImmunoTech is burning cash: its operations consume cash, a free cash flow of −$14.4M a year at the current rate against $10.0M of cash and investments: a runway of about 8 months; $3.6M of debt also comes due within a year, which would need refinancing or new money before any new financing.

Where the cash came from and went

AIM ImmunoTech: sources (+) and uses (−) of cash, Q2 2026AIM ImmunoTech: sources (+) and uses (−) of cash, Q2 2026Other financing$8.9MOperating cash flow−$4.6MCash drawn (+) / kept (−)−$4.1MNet borrowing (+) / repaid (−)−$621KShares issued$537KOther investing−$112K
AIM ImmunoTech: sources (+) and uses (−) of cash, TTM to Q2 2026AIM ImmunoTech: sources (+) and uses (−) of cash, TTM to Q2 2026Other financing$23.7MOperating cash flow−$14.4MCash drawn (+) / kept (−)−$9.4MOther investing$52K

From profit to cash

AIM ImmunoTech: net income to operating cash flow, Q2 2026AIM ImmunoTech: net income to operating cash flow, Q2 2026Net income−$3.8MDepreciation & amortization$44KGains on investments$1KPrepaid and other assets−$27KOperating cash flow−$4.6M
Non-cash charges are added back; money tied up in receivables or inventory is subtracted.

Every quarter

QuarterOperating cash flowNet borrowing (+) / repaid (−)Shares issuedCash drawn (+) / kept (−)Free cash flow
Q2 2026−$4.6M−$621K$537K−$4.1M−$4.6M
Q1 2026−$2.7M−$200K$2.0M−$2.8M−$2.7M
Q4 2025−$2.0M$2.5M—−$638K−$2.0M
Q3 2025−$5.1M—−$398K−$1.9M−$5.1M
Q2 2025−$1.5M—$105K$422K−$1.5M
Q1 2025−$2.4M—$660K$803K−$2.4M
Q4 2024−$4.0M—$32K−$786K−$4.0M
Q3 2024−$3.1M$133K$4K$2.6M−$3.1M

AIM ImmunoTech: income statement and cash flow

AIM ImmunoTech, Q2 2026: revenue $26K (+4% year over year). The chart follows the revenue to costs, profit and cash.

AIM ImmunoTech: every quarter, Q/Q and Y/Y → Open in the app

Read automatically from the company’s XBRL cash-flow statements; quarterly figures for the fourth quarter are the year less the first three. Errors are possible. Not investment advice.